Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer.
Elizabeth HagemanMia E LussierPublished in: The Annals of pharmacotherapy (2023)
Elacestrant gained FDA approval in January 2023 and can be considered in patients with HR+ HER2- advanced breast cancer and ESR1 mutations who have progressed despite therapy with either CDK 4/6i plus aromatase inhibitors (AI) or fulvestrant or chemotherapy.